Clayton A Peimer

Summary

Publications

  1. doi request reprint Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS study): 3-year data
    Clayton A Peimer
    College of Human Medicine, Michigan State University, Marquette General Healthcare, Marquette, MI 49855, USA
    J Hand Surg Am 38:12-22. 2013
  2. doi request reprint Collagenase Clostridium Histolyticum for Dupuytren Contracture: Patterns of Use and Effectiveness in Clinical Practice
    Clayton A Peimer
    Department of Surgery, College of Human Medicine, Michigan State University, Lansing Marquette General Healthcare, Marquette, MI Health Economics and Outcomes Research, Auxilium Pharmaceuticals, Inc, Malvern, PA and Center for Outcomes Research, Nashville, TN Electronic address
    J Hand Surg Am 38:2370-6. 2013

Collaborators

Detail Information

Publications2

  1. doi request reprint Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS study): 3-year data
    Clayton A Peimer
    College of Human Medicine, Michigan State University, Marquette General Healthcare, Marquette, MI 49855, USA
    J Hand Surg Am 38:12-22. 2013
    ..To evaluate long-term efficacy and safety of collagenase clostridium histolyticum (CCH) after the third year of a 5-year nontreatment follow-up study, Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study...
  2. doi request reprint Collagenase Clostridium Histolyticum for Dupuytren Contracture: Patterns of Use and Effectiveness in Clinical Practice
    Clayton A Peimer
    Department of Surgery, College of Human Medicine, Michigan State University, Lansing Marquette General Healthcare, Marquette, MI Health Economics and Outcomes Research, Auxilium Pharmaceuticals, Inc, Malvern, PA and Center for Outcomes Research, Nashville, TN Electronic address
    J Hand Surg Am 38:2370-6. 2013
    ..To collect data on the real-world effectiveness of collagenase clostridium histolyticum (CCH) during its first year of use following U.S. Food and Drug Administration approval and compare those results with clinical trial efficacy data...